Chemotherapy-Induced Cognitive Impairment (CICI): Pathophysiological Mechanisms and the Rationale for Investigating Ozone Therapy
Authors:
- Bernardino ClavoBernardino Clavo
- Gregorio Martínez-SánchezGregorio Martínez-Sánchez
- Sara E. Cazorla-RiveroSCSara E. Cazorla-Rivero
- Ángeles Cánovas-MolinaÁCÁngeles Cánovas-Molina
- José C. Román-LiñánJRJosé C. Román-Liñán
- Luis Cobiella-HernándezLCLuis Cobiella-Hernández
- Sara Ramos-VegaSRSara Ramos-Vega
- Carmen G. Pérez-SantanaCPCarmen G. Pérez-Santana
- Juan A. Díaz-GarridoJDJuan A. Díaz-Garrido
- Mario FedericoMFMario Federico
- Mora GuardamagnaMGMora Guardamagna
- Rocío Martínez-PérezRMRocío Martínez-Pérez
Open Access
- 16 November 2026
- journal article
- review article
- Published by MDPI AG in Antioxidants
- Vol. 15 (11) , 1480
Abstract
Chemotherapy-induced cognitive impairment (CICI) is an increasingly recognized complication of cancer treatment, particularly among breast cancer survivors, characterized by persistent difficulties in memory, attention, executive function, and processing speed. This review summarizes current evidence on the clinical phenotype and biological mechanisms of CICI and examines the rationale for investigating medical ozone as a redox-modulating intervention. A translational narrative review was conducted using literature published between 2000 and September 2026, retrieved from PubMed/MEDLINE, Scopus, Web of Science, and Google Scholar, complemented by manual reference-list screening. Clinical, preclinical, mechanistic, and evidence-synthesis studies were examined to critically assess the pathophysiology of CICI and the biological rationale for investigating ozone-induced redox modulation. Current evidence points to a multifactorial pathophysiology of CICI and provides a rationale for testing whether controlled redox modulation can influence some of the pathways involved, including activation of endogenous antioxidant and adaptive pathways. Preliminary evidence from chemotherapy-induced peripheral neuropathy and selected neurological or cognitive conditions provides indirect translational support, but does not establish efficacy in CICI. Medical ozone should therefore be considered investigational in this context. The hypothesis should be tested in randomized, sham-controlled trials using validated cognitive outcomes, mechanistic biomarkers, and appropriate oncological safety monitoring to determine whether ozone-induced redox adaptation can produce clinically meaningful cognitive benefit.Keywords
Funding Information
- Cabildo de Gran Canaria (CGC/2025/12551)
This publication has 62 references indexed in Scilit:
- A conceptual model of oxygen–ozone therapy as a modulator of aging via the HMGB1 pathwayBiogerontology, 2025
- Sex-related differences in the efficacy and toxicity of cancer treatmentsClinical and Translational Oncology, 2025
- The effect of non-pharmacological interventions on cognitive function in cancer: an overview of systematic reviewsSupportive Care in Cancer, 2025
- The impact of chemotherapy on cognitive performance post‐surgery in patients with colorectal cancer: A prospective cohort studyPsycho-Oncology, 2023
- Nrf2 in cancers: A double‐edged swordCancer Medicine, 2019
- Effects of major ozonated autoheamotherapy on functional recovery, ischemic brain tissue apoptosis and oxygen free radical damage in the rat model of cerebral ischemiaJournal of Cellular Biochemistry, 2018
- A prospective longitudinal study of chemotherapy-induced cognitive changes in breast cancer patientsSupportive Care in Cancer, 2010
- Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancerCancer, 2010
- Cognitive impairments associated with breast cancer treatments: results from a longitudinal studyBreast Cancer Research and Treatment, 2008
- The cognitive sequelae of standard‐dose adjuvant chemotherapy in women with breast carcinomaCancer, 2004